DNA RNA and Cells

24 Apr 2008 ReNeuron announces further pre-clinical data with its ReN003 programme for diseases of the retina
23 Apr 2008 Lorus initiates development program exploring novel route of administration for LOR-2040
21 Apr 2008 Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
18 Apr 2008 Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
17 Apr 2008 GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases
16 Apr 2008 Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
16 Apr 2008 Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients With Inherited Metabolic Diseases
14 Apr 2008 Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
09 Apr 2008 Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
08 Apr 2008 Bristol-Myers Squibb Selects Isis Drug Targeting PCSK9 as Development Candidate for Prevention and Treatment of Cardiovascular Disease
07 Apr 2008 Danish biotech company's restorative Alzheimer's product has successfully been implanted in patients
07 Apr 2008 Targeted Genetics Acquires Rights to siRNA Development Program in Huntington's Disease From Sirna Therapeutics
01 Apr 2008 Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
01 Apr 2008 Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
31 Mar 2008 Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
31 Mar 2008 Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis Platform in HIV at Keystone Symposia
28 Mar 2008 Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
20 Mar 2008 Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic
19 Mar 2008 Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
18 Mar 2008 Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
17 Mar 2008 Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
14 Mar 2008 Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
13 Mar 2008 AstraZeneca signs drug delivery collaboration
13 Mar 2008 Arrowhead Subsidiary, Calando Pharmaceuticals, Submits IND for Clinical Trial with Targeted, Nano-Delivered RNAi Therapeutic for Cancer
12 Mar 2008 Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top